Reported malignancies in clinical trials of IL‐12/23 and IL‐23 inhibitors in patients with moderate‐to‐severe psoriasis receiving active treatment with an IL‐12/23 OR IL‐23 inhibitor. This evidence concerns the gene IL23A and psoriasis.